Toxicity Clinical Trial
Official title:
Assessment of Peroxide Level in Saliva During Teeth Bleaching With 9.5% Hydrogen Peroxide Gel Using a Tray With Reservoir Versus a Tray Without Reservoir. A Randomized Clinical Trial
Assessment of peroxide level in saliva during teeth bleaching with 9.5% hydrogen peroxide gel using a tray with reservoir versus a tray without reservoir. A randomized clinical trial
Statement of the Problem There is more concern about the possible adverse effect of bleaching agent, patients report gastrointestinal mucosal irritation e.g. a burning palate, throat and minor upsets in the stomach and intestine. Some adverse effects of hydrogen peroxide as a dental bleaching agent include dentin sensitivity and/or gingival irritation led by unstable and reactive H+ free radicals and low pH from prolonged use. Peroxide is a highly reactive substance which can damage oral soft tissues and hard tissues when present in high concentrations and with exposures of prolonged duration. Several researches have focused on the problem of gel ingestion and potential peroxide release in saliva Rationale Reservoirs are modifications in the tray molds to increase the amount of bleaching material carried by the bleaching tray, seeking greater bleaching efficacy. The use of reservoirs in the bleaching trays was initially seen as positive, since higher accumulation of material could provide the patient with greater treatment efficacy. stated that there is no significant difference between groups whitened with and without reservoirs for gingival irritation or tooth sensitivity. Most authors and bleaching gel manufacturers recommend the use of reservoirs to increase the amount of product available for bleaching and to allow for complete seating of the bleaching tray, although that the reservoirs decrease tray retention and increase lab fabrication time and cost. The presence of reservoirs decreases the retention of the tray, allowing more room for the gel but also reducing the adaptation of the tray. That may cause more leakage of the material, which may lead to more peroxide level in saliva. A major concern for clinicians was the potential toxicological effect of hydrogen peroxide contacting soft tissues. A safe hydrogen peroxide exposure level (no observed effect level) was determined with catalase-deficient mice, reporting a maximum dose of 26 mg/kg/d. This corresponds to the dose level in humans, considering the conventional uncertainty factor of 100-fold, of 0.26 mg/kg/d . The safety of hydrogen peroxide products used for at home bleaching regarding peroxide release in saliva has not been fully proven. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02273713 -
The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
|
Phase 1/Phase 2 | |
Terminated |
NCT00531076 -
Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02397434 -
Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer
|
N/A | |
Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02649491 -
Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy
|
N/A | |
Active, not recruiting |
NCT03975452 -
Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer
|
N/A | |
Terminated |
NCT00618917 -
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02760823 -
Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning
|
Phase 2 | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT00890448 -
Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate
|
N/A | |
Terminated |
NCT01760356 -
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
|
||
Recruiting |
NCT06044623 -
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
|
Phase 3 | |
Completed |
NCT01091766 -
Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine
|
Phase 4 | |
Completed |
NCT05277480 -
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
|
Phase 2 | |
Recruiting |
NCT03978949 -
Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)
|
Phase 3 | |
Completed |
NCT03491371 -
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
|
N/A | |
Completed |
NCT02143219 -
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02054741 -
Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT06087718 -
Feasibility of the Maastro Applicator in Rectal Cancer
|
N/A | |
Terminated |
NCT02512809 -
Isoflurane-induced Neuroinflammation in Children With Hydrocephalus
|
Phase 3 |